Skin autofluorescence predicts cancer in subjects with type 2 diabetes
Introduction Subjects with type 2 diabetes have an excess risk of cancer. The potential role of advanced glycation end products (AGEs) accumulated during long-term hyperglycemia in cancer development has been suggested by biological studies but clinical data are missing. AGEs can be estimated by mea...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-03-01
|
| Series: | BMJ Open Diabetes Research & Care |
| Online Access: | https://drc.bmj.com/content/9/1/e001312.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126628186357760 |
|---|---|
| author | Laurence Baillet-Blanco Vincent Rigalleau Kamel Mohammedi Ninon Foussard Alice Larroumet Marine Rigo Pauline Poupon Marie Monlun Maxime Lecocq Anne-Claire Devouge Claire Ducos Marion Liebart Quentin Battaglini |
| author_facet | Laurence Baillet-Blanco Vincent Rigalleau Kamel Mohammedi Ninon Foussard Alice Larroumet Marine Rigo Pauline Poupon Marie Monlun Maxime Lecocq Anne-Claire Devouge Claire Ducos Marion Liebart Quentin Battaglini |
| author_sort | Laurence Baillet-Blanco |
| collection | DOAJ |
| description | Introduction Subjects with type 2 diabetes have an excess risk of cancer. The potential role of advanced glycation end products (AGEs) accumulated during long-term hyperglycemia in cancer development has been suggested by biological studies but clinical data are missing. AGEs can be estimated by measuring the skin autofluorescence. We searched whether the skin autofluorescence could predict new cancers in persons with type 2 diabetes.Research design and methods From 2009 to 2015, we measured the skin autofluorescence of 413 subjects hospitalized for uncontrolled or complicated type 2 diabetes, without any history of cancer. The participants were followed for at least 1 year and the occurrences of new cancers were compared according to their initial skin autofluorescences.Results The participants were mainly men (57.9%), with poorly controlled (HbA1c 72±14 mmol/mol or 8.7%±1.8%) and/or complicated type 2 diabetes. Their median skin autofluorescence was 2.6 (2.2–3.0) arbitrary units. Forty-five new cancer cases (10.9%) were registered during 4.8±2.3 years of follow-up: 75.6% of these subjects had skin autofluorescence higher than the median (χ2: p=0.001). By Cox regression analysis adjusted for age, gender, body mass index, history of smoking and renal parameters, skin autofluorescence >2.6 predicted a 2.57-fold higher risk of cancer (95% CI 1.28 to 5.19, p=0.008). This association remained significant after excluding the eight cancers that occurred in the 4 years after inclusion (OR 2.95, 95% CI 1.36 to 6.38, p=0.006). As a continuous variable, skin autofluorescence was also related to new cancers (OR 1.05, 95% CI 1.01 to 1.10, p=0.045).Conclusions Skin autofluorescence, a potential marker of glycemic memory, predicts the occurrence of cancer in subjects with type 2 diabetes. This relation provides a new clinical argument for the role of AGEs in cancer. Their estimation by measuring the skin autofluorescence may help select subjects with diabetes in cancer screening programs. |
| format | Article |
| id | doaj-art-1a742e76ed424b998d8475731a2a7b71 |
| institution | Kabale University |
| issn | 2052-4897 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Diabetes Research & Care |
| spelling | doaj-art-1a742e76ed424b998d8475731a2a7b712024-12-12T14:35:13ZengBMJ Publishing GroupBMJ Open Diabetes Research & Care2052-48972021-03-019110.1136/bmjdrc-2020-001312Skin autofluorescence predicts cancer in subjects with type 2 diabetesLaurence Baillet-Blanco0Vincent Rigalleau1Kamel Mohammedi2Ninon Foussard3Alice Larroumet4Marine Rigo5Pauline Poupon6Marie Monlun7Maxime Lecocq8Anne-Claire Devouge9Claire Ducos10Marion Liebart11Quentin Battaglini12Nutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceDepartment of Endocrinology and Diabetology, Haut-Lévêque University Hospital, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FranceIntroduction Subjects with type 2 diabetes have an excess risk of cancer. The potential role of advanced glycation end products (AGEs) accumulated during long-term hyperglycemia in cancer development has been suggested by biological studies but clinical data are missing. AGEs can be estimated by measuring the skin autofluorescence. We searched whether the skin autofluorescence could predict new cancers in persons with type 2 diabetes.Research design and methods From 2009 to 2015, we measured the skin autofluorescence of 413 subjects hospitalized for uncontrolled or complicated type 2 diabetes, without any history of cancer. The participants were followed for at least 1 year and the occurrences of new cancers were compared according to their initial skin autofluorescences.Results The participants were mainly men (57.9%), with poorly controlled (HbA1c 72±14 mmol/mol or 8.7%±1.8%) and/or complicated type 2 diabetes. Their median skin autofluorescence was 2.6 (2.2–3.0) arbitrary units. Forty-five new cancer cases (10.9%) were registered during 4.8±2.3 years of follow-up: 75.6% of these subjects had skin autofluorescence higher than the median (χ2: p=0.001). By Cox regression analysis adjusted for age, gender, body mass index, history of smoking and renal parameters, skin autofluorescence >2.6 predicted a 2.57-fold higher risk of cancer (95% CI 1.28 to 5.19, p=0.008). This association remained significant after excluding the eight cancers that occurred in the 4 years after inclusion (OR 2.95, 95% CI 1.36 to 6.38, p=0.006). As a continuous variable, skin autofluorescence was also related to new cancers (OR 1.05, 95% CI 1.01 to 1.10, p=0.045).Conclusions Skin autofluorescence, a potential marker of glycemic memory, predicts the occurrence of cancer in subjects with type 2 diabetes. This relation provides a new clinical argument for the role of AGEs in cancer. Their estimation by measuring the skin autofluorescence may help select subjects with diabetes in cancer screening programs.https://drc.bmj.com/content/9/1/e001312.full |
| spellingShingle | Laurence Baillet-Blanco Vincent Rigalleau Kamel Mohammedi Ninon Foussard Alice Larroumet Marine Rigo Pauline Poupon Marie Monlun Maxime Lecocq Anne-Claire Devouge Claire Ducos Marion Liebart Quentin Battaglini Skin autofluorescence predicts cancer in subjects with type 2 diabetes BMJ Open Diabetes Research & Care |
| title | Skin autofluorescence predicts cancer in subjects with type 2 diabetes |
| title_full | Skin autofluorescence predicts cancer in subjects with type 2 diabetes |
| title_fullStr | Skin autofluorescence predicts cancer in subjects with type 2 diabetes |
| title_full_unstemmed | Skin autofluorescence predicts cancer in subjects with type 2 diabetes |
| title_short | Skin autofluorescence predicts cancer in subjects with type 2 diabetes |
| title_sort | skin autofluorescence predicts cancer in subjects with type 2 diabetes |
| url | https://drc.bmj.com/content/9/1/e001312.full |
| work_keys_str_mv | AT laurencebailletblanco skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT vincentrigalleau skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT kamelmohammedi skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT ninonfoussard skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT alicelarroumet skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT marinerigo skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT paulinepoupon skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT mariemonlun skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT maximelecocq skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT anneclairedevouge skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT claireducos skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT marionliebart skinautofluorescencepredictscancerinsubjectswithtype2diabetes AT quentinbattaglini skinautofluorescencepredictscancerinsubjectswithtype2diabetes |